Abstract
BackgroundPyroptosis is a new type of programmed cell death, accompanied by an intense inflammatory response. Previous studies have shown that pyroptosis can modify long-chain non-coding RNA (lncRNA), thereby affecting the occurrence and progression of tumors. However, the underlying role of pyroptosis-related lncRNA in lung adenocarcinoma (LUAD) remains to be elucidated. Therefore, the purpose of our study was to evaluate the prognostic value of pyrolysis-related lncRNA in patients with LUAD.MethodsA total of 454 LUAD samples were downloaded from The Cancer Genome Atlas (TCGA) database. Pearson’s correlation coefficient was used to identify the pyroptosis-related lncRNAs. Unsupervised consensus clustering was used to identify the various LUAD molecular subtypes. A least absolute shrinkage and selection operator (LASSO) analysis was conducted to construct a prognostic signature.ResultsAn 11-lncRNA prognostic signature out of 19 identified pyroptosis-related prognostic lncRNAs was constructed. The patients with LUAD were divided into low-risk and high-risk groups. Patients in the high-risk group had higher score values and mortality. The immune score, stromal score, and estimate score were lower in the high-risk group. The risk score was an independent predictor for OS in multivariate Cox regression analyses (HR > 1, p < 0.01). BTLA, PD-1, PD-L1, CTLA, and CD47 were lower expressed in the high-risk group.ConclusionsOur study identified an 11-pyroptosis-related lncRNA signature. These findings could further clarify the role of pyroptosis in LUAD and guide the prognosis and individualized treatment of patients.
Highlights
Lung cancer is the leading cause of cancer-related death [1], great progress has recently been made in the treatment of lung adenocarcinoma (LUAD), which includes immunological therapy and targeted therapy [2, 3]
A total of 454 cases were included in this study, which were randomly separated into a training cohort for pyroptosis-related long-chain non-coding RNA (lncRNA) signature construction and a validation cohort for model validation
A total of 454 patients with LUAD were included in this analysis, and detailed clinical information is shown in Supplementary Table S3
Summary
Lung cancer is the leading cause of cancer-related death [1], great progress has recently been made in the treatment of LUAD, which includes immunological therapy and targeted therapy [2, 3]. Pyroptosis is a caspase-dependent, pro-inflammatory, programmed cell death, accompanied by the release of a large number of inflammatory factors [5]. Both apoptosis and pyroptosis are mediated by caspase. When microorganisms infect host cells exogenously or endogenously, the pattern recognition receptor located in the cytoplasm recognizes and binds to the corresponding ligands through pathogen-associated molecular patterns and damagerelated molecular patterns It forms a multi-protein complex in the cytoplasm, activates inflammatory caspase-1 and caspase-4/ 5/11, and further cleaves the GSDMD protein to perforate the cell membrane and promote the occurrence of cell pyroptosis. A previous study had confirmed that the expression of GSDMD in non-small cell lung cancer (NSCLC) tissue is significantly higher, and is related to larger tumor size, more advanced stages, and other more aggressive characteristics [11].
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
